Literature DB >> 17322888

FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis.

Zou Xiang1, Antony J Cutler, Rebecca J Brownlie, Kirsten Fairfax, Kate E Lawlor, Eva Severinson, Elizabeth U Walker, Rudolf A Manz, David M Tarlinton, Kenneth G C Smith.   

Abstract

The survival of long-lived plasma cells, which produce most serum immunoglobulin, is central to humoral immunity. We found here that the inhibitory Fc receptor FcgammaRIIb was expressed on plasma cells and controlled their persistence in the bone marrow. Crosslinking FcgammaRIIb induced apoptosis of plasma cells, which we propose contributes to the control of their homeostasis and suggests a method for therapeutic deletion. Plasma cells from mice prone to systemic lupus erythematosus did not express FcgammaRIIb and were protected from apoptosis. Human plasmablasts expressed FcgammaRIIb and were killed by crosslinking, as were FcgammaRIIb-expressing myeloma cells. Our results suggest that FcgammaRIIb controls bone marrow plasma cell persistence and that defects in it may contribute to autoantibody production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322888     DOI: 10.1038/ni1440

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  134 in total

Review 1.  Signals controlling rest and reactivation of T helper memory lymphocytes in bone marrow.

Authors:  Koji Tokoyoda; Andreas Radbruch
Journal:  Cell Mol Life Sci       Date:  2012-03-30       Impact factor: 9.261

Review 2.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 3.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

4.  Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

Review 5.  Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.

Authors:  Olivier Thaunat; Alice Koenig; Claire Leibler; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2016-02-12       Impact factor: 10.121

6.  Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse.

Authors:  To-Ha Thai; Heide Christine Patterson; Duc-Hung Pham; Katalin Kis-Toth; Denise A Kaminski; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

7.  Suppression of allergic airway inflammation and IgE responses by a class I restricted allergen peptide vaccine.

Authors:  J W Wells; K Choy; C M Lloyd; A Noble
Journal:  Mucosal Immunol       Date:  2008-10-29       Impact factor: 7.313

Review 8.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

9.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.

Authors:  Tomer Mark; David Jayabalan; Morton Coleman; Roger N Pearse; Y Lynn Wang; Richard Lent; Paul J Christos; Joong W Lee; Yash P Agrawal; Susan Matthew; Scott Ely; Madhu Mazumdar; Ethel Cesarman; John P Leonard; Richard R Furman; Selina Chen-Kiang; Ruben Niesvizky
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

10.  Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus.

Authors:  Trine N Jørgensen; Jennifer Alfaro; Hilda L Enriquez; Chao Jiang; William M Loo; Stephanie Atencio; Melanie R Gubbels Bupp; Christina M Mailloux; Troy Metzger; Shannon Flannery; Stephen J Rozzo; Brian L Kotzin; Mario Rosemblatt; María Rosa Bono; Loren D Erickson
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.